> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-77/
- Published: 2022-04-24T12:00:00.000Z
- Updated: 2026-09-14T17:41:55.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5151673

**Guide on Nanomaterial in Drugs/Biologics**  
04/22/2022 *Federal Register* notice: FDA has made available a final guidance entitled *Drug* *Products, Including Biological Products, That Contain Nanomaterials*. The document provides the agency’s current thinking on developing products that contain a nanomaterial in the finished dosage form. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-04-22/pdf/2022-08572.pdf?ref=fdaweb.com).

**Guidance on N-Acetyl-L-Cysteine Policy**  
04/22/2022 *Federal Register* notice: FDA has made available a draft guidance entitled *Policy Regarding N-acetyl-L-cysteine*. The document explains the agency’s intent to exercise enforcement discretion with respect to the sale and distribution of certain products that contain N-acetyl-L-cysteine and are labeled as dietary supplements. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-04-22/pdf/2022-08560.pdf?ref=fdaweb.com).

**Covid-19 Vaccine Guidance Update**  
04/22/2022 *Federal Register* notice: FDA is announcing the availability of an updated guidance entitled *Emergency Use Authorization for Vaccines to Prevent Covid–19* (Updated 3/31). The document has been implemented without prior comment, but it remains subject to comment under the agency’s good guidance practices. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-04-22/pdf/2022-08564.pdf?ref=fdaweb.com).

**Docket Established for Opioid Disposal**  
04/21/2022 *Federal Register* notice: FDA has established a docket to solicit public comments on a potential modification to its Opioid Analgesic Risk Evaluation and Mitigation Strategy to require that mail-back envelopes be dispensed along with education on safe disposal provided with opioid analgesics dispensed in an outpatient setting. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-04-21/pdf/2022-08372.pdf?ref=fdaweb.com).

**Modifications to Device Recognized Standards**  
04/21/2022 *Federal Register* notice: FDA is announcing modifications to its list of standards the agency recognizes for use in premarket reviews. “Modifications to the List of Recognized Standards, Recognition List Number: 057” is intended to assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices. To view the notice, click [here](https://public-inspection.federalregister.gov/2022-08571.pdf?ref=fdaweb.com).